2014
Stereotaxie Präzisionsbestrahlung bei Krebs erhöht Heilungschancen trotz Metastasen
https://www.degro.org/stereotaxie-praezisionsbestrahlung-bei-krebs-erhoeht-heilu…Austin Journal of Medical Oncology, September 14
Tumor Bed Directed Stereotactic Radiosurgery for Surgically Resected Brain Metastases
Strahlentherapie und Onkologie
September 2014, Volume 190, Issue 9, pp 786-791
Stereotactic radiosurgery for newly diagnosed brain metastases
Radiation Oncology 2014, 9:110
Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway
International Journal of Radiation Oncology • Biology • Physics
Volume 90, Issue 3, Pages 603–611, November 1, 2014
Survival Outcome After Stereotactic Body Radiation Therapy and Surgery for Stage I Non-Small Cell Lung Cancer: A Meta-Analysis
Radiation Oncology 2014, 9:210
Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review
http://www.ro-journal.com/content/9/1/210Radiation Oncology 2014, 9:112
Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients
http://www.ro-journal.com/content/9/1/112Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1061-8
Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
http://www.ncbi.nlm.nih.gov/pubmed/25442039J Urol. 2014 Aug 14. pii: S0022-5347(14)04215-3
Single-fraction radiosurgery for the treatment of renal tumors.
Der Onkologe
August 2014, Volume 20, Issue 8, pp 757-765
Stereotaktische Strahlentherapie von Metastasen
International Journal of Radiation Oncology • Biology • Physics
Volume 90, Issue 4, Pages 918–925, November 15, 2014
Single- versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Front. Oncol., 11 November 2014 | doi: 10.3389/fonc.2014.00312
SBRT for the primary treatment of localized prostate cancer: the effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227393/
